BCL2 and lymphoma: The results indicated that when Nm@MSNs-DOX/SM was used for anti-lymphoma in vivo and in vitro, the level of ROS in cells increased, the expression of Bcl-2 decreased, and the expression of Bax increased, leading to a decrease in the proportion of Bcl-2/Bax, more Bax gathered in the outer membrane of mitochondria, and a decrease in MMP, and thus promoting the occurrence of apoptosis of lymphoma cells.